SCHEMBL3340993

SCHEMBL3340993

Nc1nc(OCC2CCC2)c2cc(-c3ccn[nH]3)ccc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 10/20 0.49
NLRP3 Q96P20 3/20 0.47
TRIM58 Q8NG06 1/20 0.42
CCNA2 P20248 8/20 0.41
CCNA1 P78396 6/20 0.41
CDK1 P06493 3/20 0.41
CCNB1 P14635 3/20 0.41
CCNB2 O95067 2/20 0.40
CCNB3 Q8WWL7 2/20 0.40
JAK2 O60674 1/20 0.40
MAPK3 P27361 1/20 0.40
CLK1 P49759 1/20 0.40
CDK5 Q00535 1/20 0.40
PIN1 Q13526 1/20 0.40
MAP3K5 Q99683 1/20 0.40
AKT1 P31749 1/20 0.40
CYP4F2 P78329 2/20 0.38
CYP4A11 Q02928 2/20 0.38
MEN1 O00255 1/20 0.37
MTOR P42345 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338436 0.82 NLRP3 (0.55) NLRP3JAK2AKT1MTORMAPK10
SCHEMBL3340656 0.82 CDK2 (0.50) CDK2TRIM58CCNA2CCNA1CDK1
SCHEMBL3338737 0.80 TRIM58 (0.47) CDK2TRIM58CCNA2CCNA1CDK1
SCHEMBL3337015 0.80 TRIM58 (0.47) CDK2TRIM58CCNA2CCNA1CDK1
SCHEMBL3332879 0.80 TRIM58 (0.50) CDK2TRIM58CCNA2CCNA1CDK1
SCHEMBL3340911 0.79 NLRP3 (0.47) CDK2NLRP3CCNA2CCNA1CDK1
SCHEMBL3337046 0.79 TRIM58 (0.47) CDK2TRIM58CCNA2CCNA1MEN1
SCHEMBL3334508 0.78 TRIM58 (0.48) CDK2TRIM58CCNA2CCNA1CDK1
SCHEMBL3332960 0.77 TRIM58 (0.48) CDK2TRIM58CCNA2CCNA1CDK1
SCHEMBL3337900 0.77 TRIM58 (0.43) CDK2TRIM58CCNA2CCNA1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 CDK2 646/4885NLRP3 1683/4885TRIM58 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.